Federico Bigazzi

787 total citations
47 papers, 462 citations indexed

About

Federico Bigazzi is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Federico Bigazzi has authored 47 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 16 papers in Cardiology and Cardiovascular Medicine and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Federico Bigazzi's work include Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cardiovascular Function and Risk Factors (7 papers). Federico Bigazzi is often cited by papers focused on Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cardiovascular Function and Risk Factors (7 papers). Federico Bigazzi collaborates with scholars based in Italy, Czechia and United States. Federico Bigazzi's co-authors include Tiziana Sampietro, Francesco Sbrana, Beatrice Dal Pino, A. Bionda, Fabrizio Minichilli, Francesco Greco, Antonio L’Abbate, Khaled Qanud, William C. Stanley and Vincenzo Lionetti and has published in prestigious journals such as Circulation, Biochemical and Biophysical Research Communications and The American Journal of Medicine.

In The Last Decade

Federico Bigazzi

43 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Federico Bigazzi Italy	12	256	150	105	90	63	47	462
Qinhua Chen China	10	197 0.8×	103 0.7×	100 1.0×	58 0.6×	50 0.8×	14	420
Valérie Carreau France	13	364 1.4×	77 0.5×	65 0.6×	150 1.7×	95 1.5×	22	502
Adam Taleb United States	7	274 1.1×	129 0.9×	151 1.4×	62 0.7×	105 1.7×	12	536
Kees Hovingh Netherlands	9	149 0.6×	109 0.7×	102 1.0×	87 1.0×	48 0.8×	21	409
PA Summanen Australia	2	147 0.6×	92 0.6×	168 1.6×	234 2.6×	36 0.6×	2	752
Zhiyong Qi China	11	159 0.6×	206 1.4×	184 1.8×	50 0.6×	48 0.8×	27	584
Dong‐Feng Wu China	18	292 1.1×	141 0.9×	186 1.8×	186 2.1×	82 1.3×	39	687
John V. Mitsios Greece	13	202 0.8×	170 1.1×	107 1.0×	63 0.7×	55 0.9×	21	474
Jacy R. Crosby United States	4	234 0.9×	91 0.6×	76 0.7×	212 2.4×	77 1.2×	6	465
Shenghua Yang China	14	138 0.5×	84 0.6×	190 1.8×	98 1.1×	123 2.0×	25	536

Countries citing papers authored by Federico Bigazzi

Since Specialization

Citations

This map shows the geographic impact of Federico Bigazzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Bigazzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Bigazzi more than expected).

Fields of papers citing papers by Federico Bigazzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Bigazzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Bigazzi. The network helps show where Federico Bigazzi may publish in the future.

Co-authorship network of co-authors of Federico Bigazzi

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Bigazzi. A scholar is included among the top collaborators of Federico Bigazzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Bigazzi. Federico Bigazzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sbrana, Francesco, Federico Bigazzi, Carmen Corciulo, & Beatrice Dal Pino. (2024). Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy. European Journal of Preventive Cardiology. 31(8). e62–e64. 1 indexed citations

Sbrana, Francesco, Federico Bigazzi, Andrea Ripoli, & Beatrice Dal Pino. (2023). Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a). Transfusion and Apheresis Science. 62(3). 103660–103660. 1 indexed citations

Pino, Beatrice Dal, Francesco Sbrana, Federico Bigazzi, & Tiziana Sampietro. (2021). Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors. Transfusion and Apheresis Science. 60(6). 103258–103258. 2 indexed citations

Sampietro, Tiziana, Francesco Sbrana, Federico Bigazzi, Andrea Ripoli, & Beatrice Dal Pino. (2019). Null receptor homozygous familial hypercholesterolaemia: Quoad valetudinem long life treatment. European Journal of Preventive Cardiology. 27(19). 2105–2108. 1 indexed citations

Sbrana, Francesco, Beatrice Dal Pino, Angela Papa, et al.. (2019). Direct oral anticoagulants in lipoprotein apheresis: handle with care. Internal and Emergency Medicine. 14(7). 1171–1173. 1 indexed citations

Bigazzi, Federico, Francesco Sbrana, Sabina Zambon, et al.. (2018). Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfusion and Apheresis Science. 57(5). 661–664. 15 indexed citations

Sampietro, Tiziana, Francesco Sbrana, Emilio Pasanisi, et al.. (2017). LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease. Atherosclerosis Supplements. 30. 135–140. 6 indexed citations

Rabacchi, Claudio, Federico Bigazzi, Francesco Sbrana, et al.. (2016). Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations. Journal of clinical lipidology. 10(4). 944–952.e1. 9 indexed citations

Sampietro, Tiziana, Francesco Sbrana, Federico Bigazzi, et al.. (2015). The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. Atherosclerosis Supplements. 18. 268–272. 11 indexed citations

10.

Vecoli, Cecilia, Daniel Adlerstein, Erlet Shehi, et al.. (2014). Genetic score based on high-risk genetic polymorphisms and early onset of ischemic heart disease in an Italian cohort of ischemic patients. Thrombosis Research. 133(5). 804–810. 11 indexed citations

11.

Sbrana, Francesco, et al.. (2013). Cognitive impairment and polidistrectual atherosclerotic disease in chylomicronemia syndrome: A case report. Transfusion and Apheresis Science. 49(2). 323–327. 1 indexed citations

12.

Sbrana, Francesco, Federico Bigazzi, Patrizia Landi, et al.. (2012). High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later. Journal of Atherosclerosis and Thrombosis. 20(1). 23–31. 5 indexed citations

13.

Zimetti, Francesca, Federico Bigazzi, Francesco Sbrana, et al.. (2012). Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis. Journal of Lipid Research. 53(5). 984–989. 33 indexed citations

14.

Sbrana, Francesco, et al.. (2012). Tangier Disease. American Journal of Cardiovascular Drugs. 12(5). 303–311. 50 indexed citations

15.

Sampietro, Tiziana, Federico Bigazzi, Fabrizio Minichilli, et al.. (2009). Low high-density lipoprotein predicts death in patients with mild left ventricular dysfunction regardless of coronary atherosclerosis. Journal of Cardiovascular Medicine. 10(12). 898–905. 2 indexed citations

16.

Chandler, Margaret P., Martin E. Young, Vincenzo Lionetti, et al.. (2007). Chronic Activation of Peroxisome Proliferator-Activated Receptor-α with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure. Journal of Pharmacology and Experimental Therapeutics. 321(1). 165–171. 46 indexed citations

17.

Sampietro, Tiziana, et al.. (2005). Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy. Journal of Internal Medicine. 257(6). 523–530. 15 indexed citations

18.

Sampietro, Tiziana, Danilo Neglia, A. Bionda, et al.. (2005). Inflammatory Markers and Serum Lipids in Idiopathic Dilated Cardiomyopathy. The American Journal of Cardiology. 96(12). 1718–1720. 37 indexed citations

19.

Bigazzi, Federico, Beatrice Dal Pino, Francesco Forastiere, et al.. (2004). HDL and clinical and biochemical correlates in Italian non-smoker women. Clinical Chemistry and Laboratory Medicine (CCLM). 42(12). 1408–16. 7 indexed citations

20.

Palego, Lionella, Donatella Marazziti, Gino Giannaccini, et al.. (2000). Lack of stereoselectivity of 8-hydroxy-2(di-N-propylamino)tetralin-mediated inhibition of forskolin-stimulated adenylyl cyclase activity in human pre- and post-synaptic brain regions. Neurochemistry International. 36(3). 225–232. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact